March 5, 2023
ISATUXIMAB (SARCLISA): THE NEGOTIATIONS ARE NOW OVER!
We’re thrilled to announce that negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and the manufacturer of isatuximab (Sarclisa) have concluded after nearly 10 months of waiting! A letter of intent has been issued for the two conditions submitted: use in the following 2 situations:
-
In combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
-
In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
After CADTH (Canadian Agency for Drugs and Technologies in Health) issued a positive recommendation for isatuximab to be reimbursement under these two conditions in April 2021, Myeloma Canada pursued many advocacy initiatives with stakeholders to bring this process to a successful conclusion. We are very pleased to see that isatuximab reimbursement (under these conditions) is now a reality!